High content screening of patient-derived cell lines highlights the potential of non-standard chemotherapeutic agents for the treatment of recurrent glioblastoma

Jessica Taylor(University of Manchester), Brian Bigger(University of Manchester), Kenny Yu(Memorial Sloan Kettering Cancer Center), Ian Peers(AstraZeneca (United Kingdom)), Gareth Griffiths(Aston University), Joanna Dutko-Gwóźdź, Deniz Beyit, Omar Pathmanaban(Manchester Academic Health Science Centre), Ian Kamaly-Asl(Royal Manchester Children's Hospital), Peter Ceuppens, Rod Benson, Catherine McBain(Unknown)

Neuro-Oncology

January 1, 2018

10.1093/neuonc/nox237.024

Cited by 0

Related Papers

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

|The Lancet|2017|401

Gradient of Developmental and Injury Response transcriptional states defines functional vulnerabilities underpinning glioblastoma heterogeneity

|Nature Cancer|2021|334

Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study

|The Lancet Oncology|2021|333

Phase I trial of hES cell-derived dopaminergic neurons for Parkinson’s disease

|Nature|2025|131

Bariatric Surgery or Non-surgical Weight Loss for Idiopathic Intracranial Hypertension? A Systematic Review and Comparison of Meta-analyses

|Obesity Surgery|2016|95